Edition:
United Kingdom

Spring Bank Pharmaceuticals Inc (SBPH.OQ)

SBPH.OQ on NASDAQ Stock Exchange Capital Market

6.82USD
6:17pm BST
Change (% chg)

$-0.10 (-1.45%)
Prev Close
$6.92
Open
$6.90
Day's High
$6.98
Day's Low
$6.75
Volume
3,412
Avg. Vol
9,915
52-wk High
$15.00
52-wk Low
$6.30

Latest Key Developments (Source: Significant Developments)

Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial And Operational Results And Provides Corporate Update
Monday, 29 Apr 2019 

April 29 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL AND OPERATIONAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.32.Q1 EARNINGS PER SHARE ESTIMATE $-0.47 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $57.5 MILLION AS OF MARCH 31, 2019.  Full Article

Spring Bank Announces Results From Phase 2 Chronic Hepatitis B Trial And Additional Inarigivir Studies
Friday, 12 Apr 2019 

April 12 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK ANNOUNCES POSITIVE RESULTS FROM THE RECENTLY COMPLETED PHASE 2 CHRONIC HEPATITIS B ACHIEVE TRIAL AND ADDITIONAL INARIGIVIR STUDIES.SPRING BANK PHARMACEUTICALS INC - FAVORABLE SAFETY AND TOLERABILITY PROFILE OBSERVED ACROSS ALL DOSES STUDIED.SPRING BANK PHARMACEUTICALS INC - INARIGIVIR WAS SHOWN TO BE WELL TOLERATED AT ALL DOSES IN ACHIEVE TRIAL.SPRING BANK PHARMACEUTICALS INC - FAVORABLE SAFETY AND TOLERABILITY PROFILE OBSERVED ACROSS ALL DOSES STUDIED.  Full Article

Spring Bank Pharmaceuticals appoints Scott Smith as chairman of the board
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK PHARMACEUTICALS APPOINTS SCOTT SMITH AS CHAIRMAN OF THE BOARD.SAYS DR CHRISTIANA BARDON RESIGNED FROM THE BOARD.SMITH WILL REPLACE MARTIN DRISCOLL, SPRING BANK'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, AS CHAIRMAN OF BOARD.SPRING BANK PHARMACEUTICALS - DRISCOLL WILL CONTINUE TO SERVE AS A MEMBER OF BOARD AND AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.  Full Article

Spring Bank Pharmaceuticals Says Net Loss For Three Months Ended March 31, 2018 Was $4.9 Mln, Or $0.37 Per Share
Friday, 27 Apr 2018 

April 27 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK PHARMACEUTICALS INC - NET LOSS FOR THREE MONTHS ENDED MARCH 31, 2018 WAS $4.9 MILLION, OR $0.37 PER SHARE.SPRING BANK PHARMACEUTICALS - ANTICIPATES THAT EXISTING CASH, CASH EQUIVALENTS WILL ENABLE CO TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS INTO Q4 2019.SPRING BANK PHARMA - ANTICIPATES THAT EXISTING CASH, CASH EQUIVALENTS WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR.  Full Article

Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATIONAL RESULTS.Q4 LOSS PER SHARE $0.11.SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 2019.SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR.SPRING BANK PHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $50.6 MILLION AS OF DEC 31, 2017, COMPARED TO $25.5 MILLION AS OF DEC 31, 2016.  Full Article

Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial.Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​.Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​.Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018.  Full Article

Spring Bank Pharmaceuticals - Q3 loss per share $0.85
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals provides corporate update and reports third quarter 2017 financial and operational results.Q3 loss per share $0.85.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Spring Bank Pharmaceuticals - top-line results from second inarigivir monotherapy dosing cohort of achieve trial will be released in Q4 2017​.Spring Bank Pharmaceuticals - expects existing cash, cash equivalents, marketable securities will enable co to fund expenses, capex through 2019-end.Spring Bank - expects cash, cash equivalents, marketable securities will not be enough to fund development of inarigivir beyond Phase 2 achieve trial​.  Full Article

BVF Partners reports 5.1 pct passive stake in Spring Bank Pharmaceuticals as of Aug. 3
Friday, 11 Aug 2017 

Aug 11 (Reuters) - BVF Partners L.P: :BVF Partners L.P reports 5.1 percent passive stake in spring bank pharmaceuticals inc as of august 3, 2017 - SEC filing‍​.  Full Article

Spring Bank Pharmaceuticals posts Q2 loss per share $0.93
Monday, 31 Jul 2017 

July 31 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals provides corporate update and reports second quarter 2017 financial and operational results.Q2 loss per share $0.93.Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.Spring Bank Pharmaceuticals-sees existing cash,among others to not be sufficient for additional development of sb 9200 beyond Phase 2 achieve clinical trial.Spring Bank Pharmaceuticals-anticipates existing cash,among others will enable it to fund operating expenses, cap ex requirements through end of 2019.Spring Bank Pharmaceuticals-plans to report top-line results from second monotherapy dosing cohort of achieve global Phase 2 trial of SB 9200 in Q4.  Full Article

Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB 9200​
Monday, 10 Jul 2017 

July 10 (Reuters) - Gilead Sciences Inc :Spring Bank Pharmaceuticals Inc - ‍announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining SB 9200​.Spring Bank Pharmaceuticals - ‍under terms of clinical trial supply, collaboration agreement, Gilead will lead Phase 2 trial with input from spring bank​.  Full Article